A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.

ABSTRACT: Health technology assessment (HTA) can be used to make healthcare systems more equitable and efficient. Advances in precision oncology are challenging conventional thinking about HTA. Precision oncology advances are rapid, involve small patient groups, and are frequently evaluated without a randomized comparison group. In light of these challenges, mechanisms to manage precision oncology uncertainties are critical. We propose a life-cycle HTA framework and outline supporting criteria to manage uncertainties based on real world data collected from learning healthcare systems. If appropriately designed, we argue that life-cycle HTA is the driver of real world evidence generation and furthers our understanding of comparative effectiveness and value. We conclude that life-cycle HTA deliberatio

SUBMITTER: Regier DA 

PROVIDER: S-EPMC9596463 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature